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AnalysisBiology Boom Goes BustPolitical and industrial factors—beyond the economic head-
winds—may be causing public investment in biomedical
research to slow down around the world.It was 10 years ago that the US National
Institutes of Health (NIH)—the largest
research agency in the world—completed
an incredible 5 year project to double its
budget.
The doubling took the NIH annual
budget from $13.6 billion in 1998 to
$27.1 billion in 2003, sparked a visible
building boom at medical research cen-
ters in most major US cities, and sucked
in graduate students, postdocs, and re-
searchers from every corner of the globe.
But now, biomedical research funding
is falling back to Earth with a bump. Total
public spending on research and devel-
opment by the US federal government
has fallen for 4 years in a row (see chart).
‘‘These are absolutely the biggest cuts
we’ve seen in recent times,’’ says Mark
Hourihan, director of the R&D Budget
and Policy Program at the AmericanAdapted from appropriations progress charts
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Science.
Uncomfortably for life scientists, the
cuts in biomedical research have been
even steeper than in other disciplines.
And rather than being some kind of aber-
ration, the US pattern is being reflected
elsewhere. Of the world’s established sci-
entific powers, only Germany is consis-
tently increasing its spending (see map).
Among the emerging powers, China
and South Korea are also doing so—and
their progress is stirring up the global cir-
culation of students and ideas. But,
although these two nation’s fresh invest-
ment is significant, it is not commensurate
with the drop in spending elsewhere.
The budget of the NIH—aided by a $10
billion blast of stimulus funds—reached
about $35 billion in 2010. It has fallen
back since, as the stimulus fades. And,by the American Association for the Advancemethis year, after the unexpected passage
of an across-the-board spending cut
known as ‘‘sequestration,’’ it will fall by
another $1.5 billion to $29.3 billion.
‘‘This is a very serious blow that we’d
hoped to avoid,’’ says Francis Collins, a
geneticist and director of NIH. ‘‘About
three-quarters of the budget is already
committed, so a blow like this could fall
heavily on new proposals. That is particu-
larly worrying, as these represent our
future.’’
To try to relieve the impact of seques-
tration, several NIH institutes are shaving
5% of funds that they had already
pledged to commit this year, Collins
says. He adds that the NIH will be ‘‘look-
ing to trim back’’ the typical annual value
of a NIH’s main funding mechanism, the
RO1 grant.
Collins says he is acutely aware of the
customary hazard that, when funds
recede, experienced grant getters win
out at the expense of young people with
new ideas. ‘‘I am very concerned about
that, as are all 27 institute directors,’’ he
says, pledging to back schemes such as
the agency’s New Innovator Awards ‘‘to
provide an antidote to the conservative
response’’ that can arise from funding
cuts.nt of Science.
At US universities and medical schools,
the March implementation of the seques-
tration came as a nasty surprise, despite
the prolonged and noisy political debate
that preceded it. Jim Siedow, a plant biol-
ogist and vice provost for research at
Duke University in North Carolina, says
that the implications of the cut will
become clearer later in the year, as it
eats away at envisaged income.
‘‘We’re very worried about people
losing their grants,’’ says Siedow, noting
that, with most university costs being
fixed, ‘‘it is in personnel—postdocs and
research technicians—that savings will
have to be made.’’ He fears the climate
will continue to worsen after this year.
‘‘There’s talk of the NIH budget five years
from now being 25% less than it is now,’’
he says. At Duke, he adds, ‘‘we haven’t
had to make big nasty decisions—yet.’’
The other major scientific nations of the
English-speaking world—Canada,
Australia, and the United Kingdom—
each implemented expansions in biomed-
ical research funding of their own soon
after the NIH doubling. In each case,
2013 budgets confirm that this expansion
has now ended.
Of the main biomedical research
agencies in the three nations, the UK
Medical Research Council is probably in
the best shape. Spending there will in-crease this year by 3%, in line with a
3 year plan that allows the agency’s
budget to grow with inflation.
In Canada, a March budget allocated
an extra C$160 million to Genome Can-
ada over 3 years, as well as C$220 million
for research infrastructure. But overall
spending at the Canadian Institutes of
Health Research (CIHR) will fall by 3%.
‘‘The focus is to deal with the deficit and
throw research a few bones,’’ says Paul
Dufour, a long-time adviser on Canadian
research policy based in Quebec.
Australia’s economy, like Canada’s,
has performed relatively well since 2008,
but even so, research there has fallen
victim to austerity. Although Warwick
Anderson, a physiologist and chief execu-
tive of the National Health and Medical
Research Council, says that its 2013
budget is ‘‘basically in steady state,’’ he
admits that this ‘‘has come as a bit of a
surprise; people had been used to
growth.’’
But Australian universities complain
that last October’s midyear budget
whisked away some A$500 million in
overhead payments that they had been
planning for over the next 4 years and
that inflation is also eating into the value
of grants. ‘‘There’s been a steady chip-
ping away of what’s available,’’ says
Brendan Crabb, a microbiologist andCpresident of the Association of Australian
Medical Research Institutes (AAMRI).
Such erosion is small beer, however,
compared with the turmoil in the countries
whose economies have been hardest hit
by the financial crisis. Since 2008, Italy
and Spain have both experienced rocky
descents that have taken away about
40% of their research funding, according
to local campaigners. In neither case do
official budget figures tell the full story. In
Spain, for example, it emerged last
September that up to half of the national
research budget, allocated as ‘‘loans’’
for companies or research institutes,
hadn’t been getting spent at all.
‘‘This has been going on for a long time,
and the situation is now unsustainable,’’
says Amaya Moro-Martin, an astrobiolo-
gist at the Spanish Research Council in
Madrid. ‘‘They are dismantling the entire
scientific infrastructure of the country.’’
Moro-Martin helped found a grassroots
action group, Investigacio´n Digna (Dignify
Research), whose open protest letter to
the government has attracted 28,000 sig-
natures. A similar group, Return on
Academic Research (ROAR), is active in
Italy. There has been little sign, however,
that these scientist-activists are having
an impact on policy.
France, meanwhile, has had its share of
economic problems, and last October’sell 154, July 3, 2013 ª2013 Elsevier Inc. 17
budget granted increases of about 2%—
about the same as the rate of inflation—
to most research agencies.
‘‘The situation we’re facing is difficult,’’
saysAntioneTriller, a cell biologist at Ecole
Normale Superieure in Paris, noting that
the success rate for grants at ANR, Fran-
ce’s main grants agency, is down to
13%. Successive governments have
sought to pull away from the traditional
French model—whereby most re-
searchers hold secure positions at labora-
tories runbygovernmentagenciessuchas
CNRS—and introduce more competitive
grants, as in theUSandUK.Now that bud-
gets are falling everywhere, the security
offered by the old system has its advan-
tages, Triller says: ‘‘In a way, in a crisis sit-
uation, the French system is not so bad.’’
For the third year in a row, Germany is
the only large European nation to sub-
stantially increase science spending. In
March’s budget, funding for the Federal
Ministry of Education and Research
(BMBF) was up 6.3% to V13.75 billion.
Biomedical research will grow somewhat
less than that; a BMBF spokeswoman
said it didn’t have a precise figure due to
‘‘restructuring.’’ This is a slowdown from
9% growth last year and 11% in 2011.
With an election looming and the econ-
omy slowing, German scientists worry
that their recent spurt of funding growth
is coming to an end.
After the West’s economy hit the
buffers in 2008, research funding in the
developing countries, at least, continued
to expand. But, of the large, emerging
powers—Brazil, Russia, India, and
China—only the last seems determined
to keep that expansion going.
There is, nonetheless, a rebalancing
taking place in the flow of researchers be-
tween the ‘‘developed’’ and ‘‘developing’’
nations. In 2006, for example, Foundation
for Research Support of the State of Sa˜o
Paulo (FAPESP)—the largest research
funding agency in South America, serving
Brazil’s Sa˜o Paulo state—started a pro-
gram to attract foreign postdocs. That
year, it had hired just two postdocs from
the US, five from Italy, and none from
the UK. Last year, according to scientific
director Carlos Henrique de Brito Cruz, it
took on 19 from the United States, 14
from Italy, and 9 from Britain.
‘‘There are three things going on here,’’
Brito observes. ‘‘Brazil is becoming a18 Cell 154, July 3, 2013 ª2013 Elsevier Inc.more interesting address for a scientist.
FAPESP created a program to hire them.
And funding in the developed countries
became more difficult.’’
Even Russia, where science has strug-
gled to recover its footing ever since the
collapse of the Soviet Union, has made
some headway in addressing this bal-
ance, awarding ‘‘megagrants’’ worth
about $5 million each to a handful of prin-
cipal investigators, many of them return-
ing from positions abroad.
New institutions such as Skoltech, an
ambitious collaboration between a gov-
ernment-endowed foundation and the
Massachusetts Institutes of Technology
to build a postgraduate university outside
Moscow, are also starting to challenge
the Russian Academy of Sciences as cen-
ters of influence in Russian science.
In February 2012, India released a
national 5 year plan that promised to
sharply ramp up the budgets of the two
main health research agencies, the
Department of Biotechnology and the In-
dian Council of Medical Research. How-
ever, the Indian economy has slowed
since then; budget increases pledged
last year were not implemented, and In-
dian scientists now say they expect
none this year either.
Only in the Far East is the funding
outlook brighter. After a decade of stag-
nant funding, Japanese spending picked
up last year, and the government
announced a ‘‘stimulus package’’ in
January that will pour $11 billion into sci-
ence and technology, including $240
million specifically for stem cell research
and larger amounts across all disciplines
for infrastructure ($960 million) and indus-
try-university collaboration ($2 billion). It
isn’t known how much of that will go to
biomedical research or how long it will
take to spend; the money was disbursed
by March, but the actual expenditure will
run over 2 years or perhaps more.
Singapore’s Biomedical Research
Council has assured funding of S$ 2.4
billion over the 2011–2015 period. Its
recent effort to work with industry has
drawn in S$ 75 million of additional sup-
port from companies over the last 2 years,
says Benjamin Seet, the council’s execu-
tive director, noting the recent establish-
ment of laboratories by L’Ore´al and
Procter & Gamble on the island. ‘‘Biomed-
ical research has increasing relevancebeyond the pharmaceutical industry,’’ he
says.
South Korea has often posted double-
digit increases in its research spending
in recent years. But this slowed to just
5% in 2012, according to revised govern-
ment figures and will be lucky to match
that this year.
It is China that continues to pour new
resources into research at a rate truly sig-
nificant on a global scale.
Last year, it surpassed Japan as the
second-largest global power in research
and development, spending an estimated
$160 billion last year. The great bulk of
this, however, is for product development
in the manufacturing industry. Most of
China’s best science is in disciplines
directly supporting that, such asmaterials
science.
China’s investment in biomedical
research—which is coming from cities
and states, as well as from national
agencies in Beijing—has not been reliably
estimated. The Organization for Eco-
nomic Cooperation and Development
(OECD) reports that total Chinese govern-
ment investment in research and develop-
ment was $6.9 billion in 2011 and had
been growing at an extraordinary com-
pound rate of 20% since 2003.
But, in the absence of reliable budget
data, there is plenty of other evidence
that China is emerging as a real power in
biomedical science. According to data
published in January by the Nature Pub-
lishing Group, for example, Chinese pub-
lication in the group’s journals (which are
heavily weighted toward the life sciences)
grew 4-fold between 2008 and 2012.
China comfortably surpassed Australia
and is closing in on Japan as the largest
scientific power in the Asia-Pacific region.
China’s emergence is, however, a
bright spot in a darkening picture for
global biomedical research. When this
informal survey started in Cell 2 years
ago, almost all of those interviewed attrib-
uted any slowdown in spending to the
weak, short-term economic outlook.
It is now clear that some additional
forces are coming into play. One is the
retrenchment in the pharmaceutical in-
dustry, which is struggling to fill its drug
pipeline and has been closing down
major research laboratories. A second—
possibly related—factor may be diminish-
ing political faith in biomedical research
as a route to better and cheaper health-
care.
The drug industry announced thou-
sands of layoffs last year, notably in
Australia, Canada, and the UK—countries
whose governments had set great store in
backing biomedical research. ‘‘There’s
been amassive restructuring of the indus-
try worldwide,’’ says Mark Downs, chief
executive of the Society of Biology in
London, noting how drug companies are
now turning to universities and small
biotechnology companies for their future
product development. ‘‘The jury is still
out on whether the new model will work.’’
This change has been accompanied—
at least in the US—by adverse develop-
ments in the politics of biomedical
research. When Congress began to dou-
ble the NIH budget in 1998, the House
and Senate were dominated by ‘‘barons’’
such as Senator Mark Hatfield (Repub-
lican, Oregon) and Senator Robert Byrd
(Democrat, West Virginia), who feareddisease themselves and set great store
by the NIH’s ability to fight it. Just one
of them—Pennsylvania senator Arlen
Specter—single-handedly maneuvered a
cool $10 billion for NIH into President
Obama’s 2009 stimulus package.
Now these men have retired or died to
be replaced by congressional leaders
who have no particular attachment to
medical research. Francis Collins says
that his agency is looking out for allies.
‘‘We have supporters in both Houses of
Congress. Much of this will hang on
what leadership of the country can
achieve, to put budgetary decision-mak-
ing on a more rational basis,’’ he
says. ‘‘But we’re also fortunate that
biomedical research continues to be one
of the few issues that is not intrinsically
partisan.’’
Even so, US university administrators
worry about where NIH will find congres-
sional support in the future. ‘‘There’s a
limited number who’ve expressed an in-Cterest,’’ says Duke’s Jim Siedow. ‘‘For
some reason, the NIH has lost some of
its luster. They don’t think that it handled
the doubling very well.’’
It was the US Congress that started the
global boom in public funding for biomed-
ical research, giving the NIH more money
than any president asked for over many
decades. Now, it might be the US
Congress that lets the boom subside. If
that happens, thousands of young re-
searchers who have committed their lives
and careers to the field could be left in the
lurch.
‘‘We’ve got this system that’s pump-
primed all these young people, and
now there’s nowhere for them to go,’’
says Crabb at the AAMRI. For some,
attention is turning to what they should
be told to do instead. ‘‘Only one in ten
postdocs is going to become a principal
investigator,’’ says Downs. ‘‘This hasn’t
been conveyed to them powerfully
enough.’’Colin Macilwain
Edinburgh, UK
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